HK1093222A1 - Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy - Google Patents

Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy

Info

Publication number
HK1093222A1
HK1093222A1 HK07100300.8A HK07100300A HK1093222A1 HK 1093222 A1 HK1093222 A1 HK 1093222A1 HK 07100300 A HK07100300 A HK 07100300A HK 1093222 A1 HK1093222 A1 HK 1093222A1
Authority
HK
Hong Kong
Prior art keywords
yeast
methods
heteromultimeric polypeptides
mating strategy
synthesizing
Prior art date
Application number
HK07100300.8A
Other languages
English (en)
Inventor
James M Cregg
John Latham
Mark Litton
Randall Schatzman
Ilya I Tolstorukov
Original Assignee
Keck Graduate Inst
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keck Graduate Inst, Alder Biopharmaceuticals Inc filed Critical Keck Graduate Inst
Publication of HK1093222A1 publication Critical patent/HK1093222A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK07100300.8A 2003-10-22 2007-01-09 Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy HK1093222A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51387603P 2003-10-22 2003-10-22
PCT/US2004/035302 WO2005040395A1 (en) 2003-10-22 2004-10-22 Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy

Publications (1)

Publication Number Publication Date
HK1093222A1 true HK1093222A1 (en) 2007-02-23

Family

ID=34520146

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100300.8A HK1093222A1 (en) 2003-10-22 2007-01-09 Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy

Country Status (17)

Country Link
US (7) US8268582B2 (ja)
EP (2) EP1678314B1 (ja)
JP (3) JP4994038B2 (ja)
CN (2) CN101979650B (ja)
AU (2) AU2004283299B2 (ja)
CA (1) CA2541651C (ja)
DK (2) DK1678314T3 (ja)
ES (2) ES2630224T3 (ja)
HK (1) HK1093222A1 (ja)
HU (1) HUE033349T2 (ja)
IL (2) IL174783A (ja)
NO (1) NO20062134L (ja)
NZ (1) NZ547279A (ja)
PL (1) PL1678314T3 (ja)
PT (1) PT1678314E (ja)
SI (1) SI1678314T1 (ja)
WO (1) WO2005040395A1 (ja)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
CN101600793B (zh) * 2006-05-19 2013-06-26 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
KR100778219B1 (ko) 2006-08-28 2007-11-29 한국생명공학연구원 교배형 특이적 유전자에 의해 조절되는 반수체 제조용형질전환 효모 균주의 제조
US7795411B2 (en) * 2006-10-05 2010-09-14 Fred Hutchinson Cancer Research Center Vectors for expressing in vivo biotinylated recombinant proteins
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
JP2010517577A (ja) * 2007-02-09 2010-05-27 メディミューン,エルエルシー 酵母細胞原形質膜による抗体ライブラリー提示
US20100111966A1 (en) 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
NZ597767A (en) 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9056905B2 (en) * 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
MX2011005408A (es) 2008-11-25 2011-06-16 Alder Biopharmaceuticals Inc Antagonistas de il-6 para prevenir o tratar la trombosis.
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
JP6294585B2 (ja) 2009-09-03 2018-03-20 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗gitr抗体
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
KR20120118088A (ko) 2009-11-24 2012-10-25 앨더바이오 홀딩스 엘엘씨 Ⅰl-6에 대한 항체 및 이들의 용도
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
EP2566517B1 (en) 2010-05-04 2018-10-24 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
WO2012161956A2 (en) * 2011-05-20 2012-11-29 Alder Biopharmaceuticals, Inc. High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
JP6374789B2 (ja) 2011-05-20 2018-08-15 アルダーバイオ・ホールディングズ・エルエルシー 羞明または光嫌悪症を予防または抑制する抗cgrp抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
US10150968B2 (en) 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
KR101978534B1 (ko) * 2011-08-19 2019-08-28 앨더바이오 홀딩스 엘엘씨 변형된 미생물 이를 테면 피치아 파스토리스(pichia pastoris)에서 다수의 아단위 단백질들, 이를 테면 항체의 고역가 및 고순도 생산을 위한 다중-복사체 전략
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
JP2015533787A (ja) 2012-08-31 2015-11-26 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子1受容体(csf1r)を結合する抗体によって状態を治療する方法
CN103911371B (zh) * 2013-01-05 2016-05-04 中国科学院微生物研究所 一种酿酒酵母整合型表达载体
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
US10202630B2 (en) 2013-03-15 2019-02-12 Alderbio Holdings Llc Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
EP3754012A1 (en) 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
EP2971037B1 (en) 2013-03-15 2019-07-10 Alder Biopharmaceuticals, Inc. Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
WO2015003122A2 (en) 2013-07-03 2015-01-08 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
WO2015003114A1 (en) 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
CN112225810B (zh) 2013-08-01 2024-10-29 戊瑞治疗有限公司 无岩藻糖基化抗fgfr2iiib抗体
CN103468595B (zh) * 2013-09-24 2016-01-13 浙江海正药业股份有限公司 表达重组人血白蛋白的酵母菌、其构建方法及应用和表达重组人血白蛋白的方法
CN103710278A (zh) * 2013-12-25 2014-04-09 江南大学 一种低产尿素的工业黄酒酵母代谢工程菌及其构建方法
EP3116957B1 (en) 2014-03-11 2019-06-12 The Chemours Company FC, LLC Tailored dispersion and formation of integrated particle systems via ph responsive groups
JP6964410B2 (ja) 2014-06-23 2021-11-10 ファイヴ プライム セラピューティクス インク コロニー刺激因子1受容体(csf1r)に結合する抗体で疾患を治療する方法
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
CN107567336B (zh) 2014-10-29 2021-12-31 戊瑞治疗有限公司 癌症的联合治疗
EP3223865A4 (en) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
IL284291B1 (en) 2014-12-19 2024-10-01 Lundbeck Seattle Biopharmaceuticals Inc Human anti-ACTH antibodies and their use
AU2015369854B2 (en) 2014-12-22 2021-07-01 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
WO2016154177A2 (en) 2015-03-23 2016-09-29 Jounce Therapeutics, Inc. Antibodies to icos
EP3964527A3 (en) 2015-04-13 2022-06-15 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
US10865394B2 (en) 2015-07-27 2020-12-15 Washington University Toolkit for the production of post-translationally modified proteins
WO2017019777A1 (en) * 2015-07-27 2017-02-02 Washington University Toolkit for the production of post-translationally modified proteins
JP2018534927A (ja) 2015-10-22 2018-11-29 ジョンス セラピューティクス, インコーポレイテッド Icos発現を決定する遺伝子シグネチャー
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CA3020990A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Humanized anti-pacap antibodies and uses thereof
CN117903316A (zh) 2016-07-29 2024-04-19 朱诺治疗学股份有限公司 抗独特型抗体及相关方法
RS62589B1 (sr) 2016-11-02 2021-12-31 Jounce Therapeutics Inc Antitela na pd-1 i njihova upotreba
CA3049047A1 (en) 2017-01-20 2018-07-26 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1 antibodies and uses thereof
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
JP7299842B2 (ja) 2017-05-16 2023-06-28 ファイヴ プライム セラピューティクス インク がん治療における化学療法剤と組み合わせた抗fgfr2抗体
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
TW201932482A (zh) 2017-11-01 2019-08-16 美商奇諾治療有限公司 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
JP7391839B2 (ja) 2017-12-01 2023-12-05 ファイザー・インク 抗cxcr5抗体、その組成物及びその使用
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - cct5 결합 분자 및 이의 사용 방법
CA3087166A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
KR20200136465A (ko) 2018-03-29 2020-12-07 화이자 인코포레이티드 Lfa3 변이체 및 그의 조성물 및 용도
CN112533952B (zh) 2018-06-01 2023-03-07 大有华夏生物医药集团有限公司 治疗疾病或病况的组合物及其用途
CN113056483A (zh) 2018-07-09 2021-06-29 戊瑞治疗有限公司 结合到ilt4的抗体
CN112601761A (zh) 2018-08-13 2021-04-02 印希比股份有限公司 结合ox40的多肽及其用途
TW202024131A (zh) 2018-09-07 2020-07-01 美商輝瑞大藥廠 抗-αvβ8抗體及組合物及其用途
AU2019337759A1 (en) 2018-09-10 2021-03-11 Legend Biotech Ireland Limited Single-domain antibodies against CD33 and constructs thereof
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
JP2022504822A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
BR112021007626A2 (pt) 2018-11-01 2021-10-13 Juno Therapeutics, Inc. Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
AU2020206672A1 (en) 2019-01-07 2021-07-15 Inhibrx Biosciences, Inc. Polypeptides comprising modified IL-2 polypeptides and uses thereof
PE20211707A1 (es) 2019-01-08 2021-09-01 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp
AR119683A1 (es) 2019-01-29 2022-01-05 Juno Therapeutics Inc Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1)
WO2020185739A1 (en) 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
CN114127115A (zh) 2019-05-04 2022-03-01 印希比股份有限公司 结合CLEC12a的多肽及其用途
KR20220004750A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. Cd33 결합 폴리펩타이드 및 이의 용도
JP2022532868A (ja) 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Cd123結合性ポリペプチド及びその使用
US20220378909A1 (en) 2019-11-05 2022-12-01 Jounce Therapeutics, Inc. Methods of Treating Cancer with Anti-PD-1 Antibodies
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
WO2021113776A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
TW202143993A (zh) 2020-01-06 2021-12-01 香港商高誠生物醫藥(香港)有限公司 抗tnfr2抗體及其用途
US20230054718A1 (en) 2020-01-07 2023-02-23 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
JP2023513003A (ja) 2020-01-29 2023-03-30 インヒブルクス インコーポレイテッド Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
CA3169939A1 (en) 2020-02-28 2021-09-02 Jie Xue Anti-cd137 construct and use thereof
EP4110826A4 (en) 2020-02-28 2024-08-14 Shanghai Henlius Biotech Inc ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES
US20230149462A1 (en) 2020-04-10 2023-05-18 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
US20230151098A1 (en) 2020-04-20 2023-05-18 Jounce Therapeutics, Inc. Compositions and Methods for Vaccination and the Treatment of Infectious Diseases
CA3177921A1 (en) 2020-05-04 2021-11-11 Inhibrx, Inc. Canine pd-1-binding polypeptides and uses thereof
EP4157462A1 (en) 2020-06-02 2023-04-05 Dynamicure Biotechnology LLC Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
AR122863A1 (es) 2020-07-02 2022-10-12 Inhibrx Inc Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
WO2022026763A1 (en) 2020-07-29 2022-02-03 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
US20230324408A1 (en) 2020-08-05 2023-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
MX2023001707A (es) 2020-08-10 2023-05-04 Shanghai Xunbaihui Biotechnology Co Ltd Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
CN111944708B (zh) * 2020-08-27 2022-04-01 宜宾五粮液股份有限公司 高产乙酸异戊酯的酵母及其应用
US20240011016A1 (en) * 2020-11-23 2024-01-11 Merck Sharp & Dohme Llc Full-length human immunoglobulin g antibody libraries for surface display and secretion in saccharomyces cerevisiae
US11720540B2 (en) 2020-12-30 2023-08-08 Itron, Inc. Secure blockchain data recovery
JP2024505600A (ja) 2021-02-03 2024-02-06 モーツァルト セラピューティクス, インコーポレイテッド 結合剤およびそれを使用する方法
MX2023009567A (es) 2021-02-19 2023-08-22 Inhibrx Inc Formulaciones de polipeptidos de union a dr5.
WO2022187863A1 (en) 2021-03-05 2022-09-09 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
EP4314049A1 (en) 2021-03-25 2024-02-07 Dynamicure Biotechnology LLC Anti-igfbp7 constructs and uses thereof
US20240209080A1 (en) 2021-04-10 2024-06-27 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
JP2024516631A (ja) 2021-04-23 2024-04-16 プロファウンドバイオ ユーエス カンパニー 抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4359794A1 (en) 2021-07-13 2024-05-01 Keystone Bio, Inc. Diagnostics for porphyromonas gingivalis
WO2023004305A1 (en) 2021-07-20 2023-01-26 Inhibrx, Inc. Cd8-targeted modified il-2 polypeptides and uses thereof
TW202321283A (zh) 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8結合多肽及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023133393A1 (en) 2022-01-05 2023-07-13 Inhibrx, Inc. Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
IL314073A (en) 2022-01-05 2024-09-01 Inhibrx Biosciences Inc Gamma delta T-cell binding polypeptides and uses thereof
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023196943A1 (en) 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
WO2023215810A1 (en) 2022-05-05 2023-11-09 Inhibrx, Inc. Albumin-binding polypeptides and uses thereof
WO2023230432A1 (en) 2022-05-23 2023-11-30 Inhibrx, Inc. Dr5 agonist and iap antagonist combination therapy
WO2023230488A1 (en) 2022-05-23 2023-11-30 Cereius, Inc. Her2-binding agents and uses thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
TW202409086A (zh) 2022-06-11 2024-03-01 美商英伊布里克斯公司 FcRn-結合多肽及其用途
WO2024006975A1 (en) 2022-07-01 2024-01-04 Bristol-Myers Squibb Company Methods for antibody humanization
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
US20240228664A9 (en) 2022-07-22 2024-07-11 Bristol-Myers Squibb Company Antibodies Binding to Human PAD4 and Uses Thereof
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024040216A2 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof
WO2024044779A2 (en) 2022-08-26 2024-02-29 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
US20240226298A1 (en) 2022-12-13 2024-07-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024216064A1 (en) 2023-04-14 2024-10-17 Twist Bioscience Corporation Compositions and methods related to dkk1 binders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
GB8927480D0 (en) 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
WO1991002057A1 (en) 1989-08-09 1991-02-21 Delta Biotechnology Limited Polypeptide production in fungi
US5202422A (en) 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JPH06506117A (ja) * 1991-04-01 1994-07-14 メルク エンド カンパニー インコーポレーテッド ピキア(Pichia)蛋白質分解活性に影響する遺伝子およびその使用
US5330901A (en) * 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
DK0682710T3 (da) 1993-02-10 2004-03-01 Unilever Nv Isolationsmetode, ved hvilken der anvendes immobiliserede proteiner med specifikke kapaciteter
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6232111B1 (en) * 1996-04-10 2001-05-15 Merck & Co., Inc. Method for improving culture medium for recombinant yeast
US20010036647A1 (en) * 1998-10-22 2001-11-01 Prabhakara V. Choudary Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6258559B1 (en) * 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
WO2003016525A1 (fr) 2001-08-16 2003-02-27 Kansai Chemical Engineering Co., Ltd. Procede de production d'alcool a partir d'amidon
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
CA2499467A1 (en) * 2002-09-20 2004-04-01 Cym1P A/S Methods for increasing the production of a recombinant polypeptide from a host cell

Also Published As

Publication number Publication date
US10259883B2 (en) 2019-04-16
EP1678314A1 (en) 2006-07-12
CA2541651A1 (en) 2005-05-06
ES2393555T3 (es) 2012-12-26
ES2630224T3 (es) 2017-08-18
DK2330201T3 (en) 2017-07-24
US20080003643A1 (en) 2008-01-03
SI1678314T1 (sl) 2013-01-31
US20200031949A1 (en) 2020-01-30
EP1678314B1 (en) 2012-09-05
IL211402A (en) 2015-08-31
US8268582B2 (en) 2012-09-18
PL1678314T3 (pl) 2013-02-28
US20160068849A1 (en) 2016-03-10
US8709756B2 (en) 2014-04-29
US10155819B2 (en) 2018-12-18
JP5982504B2 (ja) 2016-08-31
AU2009213095B2 (en) 2012-01-19
US20060270045A1 (en) 2006-11-30
CA2541651C (en) 2011-05-24
JP4994038B2 (ja) 2012-08-08
IL211402A0 (en) 2011-04-28
JP2012095669A (ja) 2012-05-24
JP2015062433A (ja) 2015-04-09
US9873746B2 (en) 2018-01-23
HUE033349T2 (en) 2017-11-28
EP2330201B1 (en) 2017-04-05
US20140206039A1 (en) 2014-07-24
CN1871359B (zh) 2010-11-17
CN101979650A (zh) 2011-02-23
JP2007508847A (ja) 2007-04-12
US20110183402A1 (en) 2011-07-28
EP1678314A4 (en) 2007-03-07
AU2009213095A1 (en) 2009-10-08
CN1871359A (zh) 2006-11-29
NO20062134L (no) 2006-06-26
CN101979650B (zh) 2015-09-16
US7927863B2 (en) 2011-04-19
AU2004283299A1 (en) 2005-05-06
PT1678314E (pt) 2012-11-27
US11447560B2 (en) 2022-09-20
DK1678314T3 (da) 2012-12-03
IL174783A (en) 2012-10-31
US20130029880A1 (en) 2013-01-31
IL174783A0 (en) 2006-08-20
US20160297887A9 (en) 2016-10-13
EP2330201A1 (en) 2011-06-08
AU2004283299B2 (en) 2009-06-18
NZ547279A (en) 2008-04-30
WO2005040395A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
IL211402A0 (en) Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
IL164549A (en) Method of producing a functional polypeptide in a microalgal plastid
AU2003300463A1 (en) Classification of deviations in a process
IL175353A0 (en) Optimized expression of hpv 58 li in yeast
EP1625474A4 (en) DEVICE FOR MULTIMEDIA CONTROL OF CELLULAR TELEPHONES
AU2002952043A0 (en) Methods for making composite tiles
AU2003210137A1 (en) Method for producing recombinant proteins in micro-organisms
GB0416341D0 (en) Re-entry strategy from boost mode to egr mode
AU2003252564A1 (en) A ginseng preparation using vinegar and process for thereof
AU2003242080A1 (en) White powder and method for production thereof
EP1568763A4 (en) PROCESS FOR PRODUCING A FERMENTED BEVERAGE
AU2003900184A0 (en) Method of operating a fuel cell
AU2003264657A1 (en) Method for designing peptides
AU2003201854A1 (en) PROCESS FOR PRODUCING KiSS-1 PEPTIDE
GB0308129D0 (en) Diesel/lpg conversion kit
AU2003301826A1 (en) Connections for geometric modeling kit
AU2003241258A1 (en) Method and arrangement related to a dough forming
AU2002323137A1 (en) Methods and compositions for use in selectively producing a protein in telomerase expressing cells
EP1596452A4 (en) MANUFACTURING METHOD FOR A FUEL CELL PARAMETER
AU2003296288A1 (en) Method for producing low-viscous marine fuel
AU2003288013A1 (en) Method for producing composite moulded bodies
EP1546186A4 (en) PROCESS FOR SYNTHESIS OF PEPTIDES
HK1076992A1 (en) Method for producing instant noodles and instant noodles
AU2003275657A1 (en) Process for producing matsutake mushroom mycelium
AU2003273715A1 (en) Improved method for protein production in plant cells

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181025